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One of the challenges in the development of methionine
aminopeptidase (MetAP) inhibitors as antibacterial and
anticancer agents is to define the metal ion actually used by
MetAP in vivo and to discover MetAP inhibitors that can
inhibit the metalloform that is relevant in vivo. Two distinct
classes of novel nonpeptidic MetAP inhibitors that are not
only potent but also highly selective for either the MnII or CoII
form have been identified. Three crystal structures of
Escherichia coli MetAP complexed with the metalloform-
selective inhibitors 5-(2,5-dichlorophenyl)furan-2-carboxylic
acid (2), 5-[2-(trifluoromethyl)phenyl]furan-2-carboxylic acid
(3) and N-cyclopentyl-N-(thiazol-2-yl)oxalamide (4) have
been solved and analysis of these structures has revealed the
structural basis for their metalloform-selective inhibition. The
MnII-form selective inhibitors (2) and (3) both use their
carboxylate group to coordinate with the two MnII ions at the
dinuclear metal site and both adopt a non-coplanar conforma-
tion for the two aromatic rings. The unique coordination
geometry of these inhibitors may determine their MnII-form
selectivity. In contrast, the CoII-form selective inhibitor (4)
recruits an unexpected third metal ion, forming a trimetallic
enzyme–metal–inhibitor complex. Thus, an important factor in
the selectivity of (4) for the CoII form may be a consequence
of a greater preference for a softer N,O-donor ligand for the
softer CoII.
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1. Introduction
Methionine aminopeptidase (MetAP) removes the N-terminal
methionine residue from nascent proteins in all cells (Brad-
shaw et al., 1998). Prokaryotic cells express only one MetAP,
which has been shown to be essential by gene deletion from
Escherichia coli (Chang et al., 1989) and Salmonella typhi-
murium (Miller et al., 1989). MetAP is therefore a potential
target for the development of novel broad-spectrum anti-
bacterial agents (Vaughan et al., 2002). Eukaryotic cells have
two types of MetAP (type I and type II; Arfin et al., 1995). The
anti-angiogenic compounds fumagillin, TNP-470 and ovalicin
are potent inhibitors of human type II MetAP (Griffith et al.,
1997, 1998; Sin et al., 1997), while the antiproliferative
bengamides inhibit both types of human MetAP (Towbin et
al., 2003), suggesting that the human MetAPs may also serve
as targets for the development of new anticancer agents.
MetAP was initially characterized as a CoII enzyme because
of the reproducible activation of the apoenzyme by CoII
(Roderick & Matthews, 1993; Arfin et al., 1995). Early X-ray
structures of MetAPs with or without a ligand bound
(Lowther & Matthews, 2000) all show a dinuclear metal site
that is formed by five conserved residues Asp97, Asp108,
His171, Glu204 and Glu235 (E. coli MetAP numbering) and
filled with two CoII ions. However, other divalent metals such
as MnII, NiII, ZnII and FeII have also been shown to activate
the enzyme in vitro (Li et al., 2003; D’Souza & Holz, 1999). It is
not known which metalloforms of MetAP are the most
important in vivo, but speculation has favored the FeII, ZnII or
MnII forms for this role (Walker & Bradshaw, 1998; D’Souza &
Holz, 1999; Wang et al., 2003). Most MetAP inhibitors were
discovered by screening against the CoII form of the enzyme in
vitro, but potent inhibition of this metalloform has not trans-
lated into effective antibacterial (Oefner et al., 2003; Schiff-
mann et al., 2005) or anti-angiogenic (Garrabrant et al., 2004)
activity. We have shown previously that inhibitors of the CoII
form of MetAP do not necessarily inhibit other metalloforms
(Li et al., 2003; Ye et al., 2004). Thus, although there are many
reasons that an in vitro active compound may be inactive in
vivo, such as absorption, metabolism etc., one of the reasons
for the apparent lack of antibacterial and anti-angiogenic
activities may be a disparity between the metalloform tested in
vitro and that which is important in vivo. Clearly, in order to
design MetAP inhibitors as antibacterial and anticancer
agents, it is essential to know which metalloforms of MetAP
are relevant in vivo and to identify appropriate inhibitors for
them.
By screening a diverse chemical library of small organic
compounds we have identified two distinct classes of novel
nonpeptidic MetAP inhibitors: each has a unique structural
scaffold and each comprises several potent inhibitors highly
selective for either the MnII or the CoII form of E. coli MetAP
(Ye et al., 2004). The typical MnII-form selective inhibitor (1)
(Fig. 1) inhibits the CoII, MnII, NiII and FeII forms of E. coli
MetAP with IC50 values of 154, 0.24, >200 and 182 mM,
respectively, while the typical CoII-form selective inhibitor (4)
(Fig. 1) inhibits the four metalloforms with IC50 values of
0.067, 53, 1.0 and 46 mM, respectively. The MnII-form selective
inhibitor (1) was crystallized with the MnII form of E. coli
MetAP; the X-ray structure showed that this inhibitor fits into
a hydrophobic pocket with its carboxylate group coordinating
with both MnII ions at the dinuclear metal site (Ye et al., 2004).
To determine whether the binding mode of (1) to MnII-MetAP
is general and to help elucidate the chemical basis for metal-
loform-selective MetAP inhibition in greater detail, we have
now carried out structural studies of E. coli MetAP in complex
with the additional metalloform-selective inhibitors. Here, we
report two new X-ray crystal structures of the MnII form of
E. coli MetAP and one new structure of the CoII form, each
complexed with a different metalloform-selective inhibitor
[(2), (3) and (4)]. Analysis of these complexes provides insight
into important structural features of the ligands that are
important for metalloform-selective inhibition.
2. Materials and methods
2.1. Preparation of the protein and compounds
The recombinant E. coli MetAP was purified as an apo-
enzyme (Li et al., 2003). Compounds (1)–(4) were purchased
from ChemBridge (San Diego, CA, USA) and characterized
by 1H and 13C NMR and high-resolution mass spectrometry.
Their inhibitory activities on the CoII, MnII, NiII and FeII forms
of E. coli MetAP have been described previously (Huang et
al., 2005; Ye et al., 2004). Compounds (2) and (3) inhibited the
MnII form with IC50 values of 0.693 and 0.290 mM, respectively.
2.2. Crystallization conditions
Initial crystallization conditions were determined using
Crystal Screen and Index HT kits in 96-well sitting-drop plates
(Hampton Research) at room temperature. Final crystals of
the enzyme–inhibitor complexes were obtained independently
by the hanging-drop vapour-diffusion method at 291–293 K.
Inhibitors (200 mM in DMSO) were added to concentrated
apoenzyme (12 mg ml1, 0.4 mM) in 10 mM MOPS pH 7.0 at
an inhibitor:apoenzyme concentration ratio of 5:1. Hanging
drops contained 3 ml protein solution mixed with 3 ml reservoir
solution. The reservoir solution consisted of 10–15% PEG
20 000, 0.1 M MES pH 6.5 and 2 mM MnCl2 for compounds
(2) and (3) or 33% PEG 3350, 0.1 M Bis-Tris pH 6.5, 0.2 M
NH4OAc and 1.2 mM CoCl2 for compound (4).
2.3. Data collection and structural refinement
Crystals were mounted on an R-AXIS IV imaging-plate
detector with a Rigaku rotating-anode generator operated at
50 kV and 100 mA. Images were collected over 180 in 0.5
increments at 100 K. Data for these structures were processed
with the XDS package (Kabsch, 1993). Structural solutions
were achieved using CCP4 (Collaborative Computational
Project, Number 4, 1994). Structures were solved with the
program AMoRe using an available E. coli MetAP structure
(PDB code 2mat; Lowther, Orville et al., 1999) as the search
model. Model building was carried out using O (Jones et al.,
1991) and crystallographic refinement was performed using
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Figure 1
Structures of the inhibitors used for crystallization and structure solution. Inhibitors (1), (2) and (3) are MnII-form selective, while inhibitor (4) is CoII-
form selective.
CNS (Brünger et al., 1998). The refinements were monitored
with the free R factor throughout the whole refinement
process, with 5% of the total number of reflections set aside.
The initial crystallographic R factors were around 35% and
the refinement process included simulated annealing to a
starting temperature of 4000 K, positional refinement, indivi-
dual B-factor refinement and addition of water molecules. The
inhibitors were modeled in using O according to the electron
densities shown in 2Fobs  Fcalc and Fobs  Fcalc maps. These
electron-density maps were examined with different contour
levels. The 2Fobs  Fcalc map was contoured around 1.0, while
the Fobs  Fcalc map was contoured at around 3.0 and around
3.0. The inhibitors were modelled considering the expected
stereochemistry deduced from small-molecule structures. The
models were found to fit the electron-density maps superbly. A
refinement library has been constructed for this stereo-
chemistry to restrain the refinement with CNS. Model building
and crystallographic refinement was performed iteratively.
When the inhibitor model was complete, it was included in the
refinement with the restraint of the above-mentioned stereo-
chemical library. The free R factor continued to fall through
several further rounds of refinements without simulated
annealing. Final coordinates were analyzed using
PROCHECK (Laskowski et al., 1993). The resulting electron-
density maps showed clear densities for most of the atoms
except for a few side chains on the molecular surface. It should
be noted that there are two protein molecules in the CoII
complex structure with inhibitor (4), which has not been
reported for previous structures of E. coli MetAP. The two
molecules were refined independently. Overlay of the two
molecules showed no significant differences except for a few
surface side chains. Atomic coordinates were examined and
superimposed with PyMOL (DeLano, 2002). All drawings for
protein structure in the figures were generated using PyMOL.
3. Results
3.1. Overall structure of E. coli MetAP in the MnII and CoII
forms complexed with the metalloform-selective inhibitors
The crystals generated by the hanging-drop method
consistently produced high-quality diffraction data for struc-
tural solution to resolutions of 1.6–1.7 Å (Table 1). All three
new structures have the typical ‘pitta-bread’ fold found in
other MetAPs with a single molecule of inhibitor bound
(Fig. 2). The two structures in the MnII form with MnII-form
selective inhibitors (2) and (3) contain two MnII ions at the
dinuclear metal site (Fig. 3a). In contrast, the CoII-form
structure with the CoII-form selective inhibitor (4) contains a
third CoII ion in addition to the two CoII ions at the normal
dinuclear site (Fig. 3b). Other than the difference in number of
metal ions at the substrate- and inhibitor-binding pocket, the
structures of the enzyme per se are very similar in the MnII
form and in the CoII form. The structures were aligned by
minimizing the root-mean-square deviation (r.m.s.d.) between
the protein backbone atoms. The r.m.s.d. is 0.104 Å between
the two MnII-form complexes with (2) and (3). The r.m.s.d.
differences between the MnII-form enzymes and the CoII-form
enzyme were slightly larger at 0.277 and 0.299 Å.
3.2. Binding of MnII-form selective inhibitors (2) and (3) to
the MnII form of MetAP
Common features of the MnII-form selective inhibitors (2)
and (3) bound to E. coli MetAP are that both use their
carboxylate group to coordinate with the two MnII ions at the
dinuclear metal site and both adopt a non-coplanar or twisted
conformation for the two aromatic rings (Fig. 3a), consistent
with our previously reported structure of E. coli MetAP
complexed with (1) (Ye et al., 2004). The twisted conformation
found in all of the MnII-form selective inhibitors (1)–(3) is in
agreement with the requirement of a small hydrophobic ortho-
substitution on the phenyl ring for inhibitory activity (Ye et al.,
2004; Huang et al., 2005). Recognizing this requirement will be
important in the design of future inhibitors. It is well known
that most ortho-substituted biphenyl derivatives show a
twisted conformation. The average twist angle for 2-fluoro-,
2-chloro- and 2-bromobiphenyl derivatives in the Cambridge
Structural Database is 47, 53 and 61, respectively (Leroux,
2004). This twisting is usually explained in terms of repulsion
between ortho H atoms or substituents in the planar confor-
mation. In phenylfurans such as (1)–(3), these steric inter-
actions would be expected to be slightly less than in biphenyls.
This is in accord with the lesser twist angles observed in the
MetAP complexes of (1)–(3), which are 41.5 for (1), 32.0 for
(2) and 52.9 for (3), suggesting that in general the phenyl-
furan-based inhibitors dock into the active site in a confor-
mation that may correspond to a minimum-energy solution
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Table 1
X-ray data-collection and refinement statistics.
Values given in parentheses correspond to the outer shell of data.
Inhibitor (2) (3) (4)
Inhibitor code FC2 FC3 CT0
PDB code 2evm 2evc 2evo
Metal ion MnII MnII CoII
Space group P21 P21 P21
Unit-cell parameters
a (Å) 37.8 37.8 49.2
b (Å) 60.2 60.2 63.4
c (Å) 50.4 50.4 75.3
 () 104.5 104.5 108.5
X-ray data collection
Resolution range (Å) 50–1.7 (1.8–1.7) 50–1.6 (1.7–1.6) 50–1.7 (1.8–1.7)
Collected reflections 84667 102291 161123
Unique reflections 23634 27140 43944
Completeness (%) 98 (96) 93 (90) 92 (88)
I/(I) 23.3 (14.1) 25.6 (12.3) 20.2 (7.0)
Rmerge (%) 2.8 (6.4) 2.7 (7.1) 4.6 (16.1)
Refinement statistics
R (%) 21.5 21.0 21.3
Rfree (%) 24.8 22.9 24.1
R.m.s.d. bonds (Å) 0.005 0.005 0.005
R.m.s.d. angles () 1.340 1.330 1.350
No. of solvent molecules 180 175 271
hBi enzyme (Å2) 17.7 18.0 14.4
hBi inhibitor (Å2) 11.9 16.8 21.0
hBi water (Å2) 24.7 26.0 19.6
conformation. This in turn would enhance their binding by
decreasing the fraction of binding energy that would be
‘wasted’ distorting the molecule into a less-favorable confor-
mation in the bound state. Adoption of this conformation is
further enforced by binding of the required small hydrophobic
ortho-substituents in a small cavity at the bottom of the main
hydrophobic binding pocket.
3.3. The metal site in the MnII-form enzymes with an
inhibitor bound
The dinuclear metal site in the MnII-form enzymes is similar
to those in the CoII form reported by Lowther & Matthews
(2000) in terms of the conserved residues for ligation to the
metal ions (Figs. 4a and 4b). The inhibitors use their carboxyl
groups to form a bidentate ligation to the MnII ion designated
Mn1; this metal has been suggested to bind with high affinity
and to be essential for catalysis (D’Souza et al., 2000). One of
the two carboxylate O atoms of the inhibitor also ligates to the
other MnII (designated Mn2). A strictly conserved water
molecule (w5) found in both the MnII-form structures is also
coordinated to Mn2. Thus, both MnII ions are hexacoordinate
with octahedral geometry. The peptidic inhibitor AHHpA-
Ala-Leu-Val-Phe-OMe was developed as a presumed transi-
tion-state analog inhibitor of MetAP [AHHpA is (3R)-amino-
(2S)-hydroxyheptanoic acid] (Keding et al., 1998) and its
complex with the CoII form of E. coli MetAP was described in
Lowther, Orville et al. (1999). When this structure is super-
imposed with our structures, the O atoms from the hydroxyl
and carbonyl groups in the AHHpA moiety occupy the same
research papers
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Figure 3
Close-up views of inhibitors (2) and (4) bound at the active-site pocket of E. coli MetAP. (a) The MnII-form selective inhibitor (2) bound to the MnII-
form enzyme and (b) the CoII-form selective inhibitor (4) bound to the CoII-form enzyme. Two MnII ions are shown as green spheres in (a) and three CoII
ions are shown as magenta spheres in (b). The inhibitors are shown in stick representation (oxygen, red; nitrogen, blue; chlorine, green; sulfur, orange;
carbon, yellow). Protein residues are shown as a solid surface (carbon, grey).
Figure 2
Overall structure of E. coli MetAP complexed with (2) as a ribbon
drawing. MnII ions are shown as two green spheres and the inhibitor is
shown as in stick representation (carbon, yellow; oxygen, red; chlorine,
green). Secondary structures are colored cyan for -helices, magenta for
-sheets and orange for loops.
positions as the two carboxyl O atoms of our furan-based
MnII-form selective inhibitors and the N atom from the amino
group of the AHHpA moiety takes up the position of the
conserved water molecule (w5) in our structures.
3.4. Binding of the CoII-form selective
inhibitor (4) to the CoII form of MetAP and
the metal site in the CoII-form complex
Compound (4) inhibits the CoII form of
E. coli MetAP both potently and selectively
(Ye et al., 2004). The binding mode of this
inhibitor at the active-site pocket has now
been revealed by the X-ray structure with
inhibitor (4) bound (Figs. 3b and 4c).
Surprisingly, inhibitor (4) makes no direct
interaction with either of the CoII ions at the
usual dinuclear metal site (Co1 and Co2).
Instead, its oxalamide core acts as a biden-
tate N,O-donor ligand toward an unex-
pected third CoII ion (Co3) situated not far
from Co1 and Co2. Co3 is clearly octa-
hedral, with two waters (w1 and w2) trans to
the N,O-donor (4) in the meridional plane.
One of the apical ligands is an imidazole
nitrogen furnished by the side chain of
His79. This is the only direct interaction
between Co3 and the enzyme, which prob-
ably explains why trimetallic forms of the
enzyme are unknown in the absence of an
auxiliary metal-coordinating ligand such as
(4). The second apical ligand is a water
molecule (w3). Co1 and Co2 at the typical
dinuclear site are coordinated in the usual
way. In crystal structures of other MetAPs in
the CoII form with various ligands, Co1 and
Co2 can be either pentacoordinate or
hexacoordinate (Lowther & Matthews,
2000). These two CoII ions share two
-carboxylato ligands furnished by residues
Asp108 and Glu235 and a -aquo ligand
(w4) that can be replaced by a donor O atom
of substrates or inhibitors. It is interesting to
note that the water molecule w3 interacts
simultaneously with Co3, an imidazole
nitrogen from the side chain of His178 and
two other water molecules (w4 and w5) that
are coordinated to Co1 and Co2. These
hydrogen-bonding and ionic (coordination)
interactions in this extended array obviously
reinforce one another, which is likely to
contribute to the overall stability of the
complex and to the high affinity of inhibitor
(4) for the CoII form of the enzyme. This
mode of binding of a third CoII ion and the
extended network it engages in are similar
to those reported for thiabendazole and 2-
picolinamidothiazole in complex with CoII-MetAP (Schiff-
mann et al., 2005) and those reported by us recently for a
quinolinyl sulfonamide in complex with the MnII and CoII
forms of E. coli MetAP (Huang et al., 2006). In addition to the
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Figure 4
Stereoviews of inhibitors (2), (3) and (4) at the enzyme active site. Unbiased Fobs  Fcalc
electron-density maps showing the inhibitors and metal ions are contoured at 3. (a) The
MnII-form selective inhibitor (2) with the MnII-form enzyme. (b) The MnII-form selective
inhibitor (3) with the MnII-form enzyme. (c) The CoII-form selective inhibitor (4) with the
CoII-form enzyme. For clarity, only the five conserved residues forming the common dinuclear
metal site (Asp97, Asp108, His171, Glu204 and Glu235) plus His79 and His178 are shown.
Protein residues are colored grey for carbon, red for oxygen and blue for nitrogen. Inhibitors
are colored the same way, except that carbons are yellow, sulfurs orange, chlorines green and
fluorines cyan. MnII ions are shown as green spheres, while CoII ions are shown as magenta
spheres. Water molecules are shown as smaller red spheres. Hydrogen bonds and metal
interactions are shown as black dashed lines.
coordination interactions of (4) with Co3, the thiazole moiety
of (4), which is coplanar with the oxalamide core, also occu-
pies part of the S1 subsite, a hydrophobic pocket formed by
residues Cys59, Tyr62, Tyr65, Cys70, Phe177 and Trp221.
Finally, the cyclopentyl group of (4) is situated at the mouth of
the substrate-binding pocket, where it is exposed to solvent
water. This latter hydrophobic interaction may explain the
differential binding and inhibitory activity of various analogs
of (4) that have different groups in place of the cyclopentyl
moiety (Ye et al., 2004).
3.5. Comparison of different metalloforms of MetAP
Currently available structures of MetAP are primarily those
of CoII enzymes, although several structures of the MnII form
(PDB codes 1xnz, 1wkm, 1r5h, 1r5g, 1r58) or the ZnII form
(PDB codes 1kq9, 1kq0) have appeared recently in the
literature (Ye et al., 2004; Copik et al., 2005; Sheppard et al.,
2004) and in the PDB. Structural information for a broader
range of MetAP metalloforms is vital for understanding
metalloform-selective inhibition as observed in vitro and for
developing active site-directed inhibitors (i.e. metal-directed
ligands) that are effective in vivo. To test the hypothesis that
discrimination between CoII and MnII metalloforms by ligands
could be related to different coordination geometries around
metal ions m1 and m2, we have compared the relevant metal–
ligand distances in these structures and others currently
available in the MnII and CoII forms (Table 2). These
comparisons are necessarily approximate because of differ-
ences in the resolution of the various crystal structures
considered. However, it is clear that there are no major
changes in metal coordination among various complexes in
the MnII form or among various MetAPs in the CoII form. At
least for MetAPs in the MnII form, the metal–donor distances
are consistent with many other MnII metalloenzymes in the
literature (Harding, 2001). On the other hand, there seems to
be a significant difference in the m1—m2 distance between the
two metalloforms, with the Mn—Mn distance being about 8%
longer than the corresponding Co—Co distance. Although it is
not clear whether this difference will hold up as more exam-
ples become known, it is important to relate this directly to the
ability of simple ligands to discriminate strongly between
MetAPs in the MnII form and in the CoII form.
4. Discussion
As an exoproteinase, MetAP has a hydrophobic substrate-
binding pocket that is sized to accommodate the N-terminal
methionine residue of nascent proteins for processing. As
shown in previous X-ray structures, two metal ions are situ-
ated deep in the active-site pocket (Lowther & Matthews,
2000) and it has been proposed that the metal ions directly
participate in the peptide-bond cleavage by activating a water
molecule and orienting the substrate in a productive confor-
mation (Lowther & Matthews, 2002). Any blockage of entry of
a MetAP substrate will prevent the hydrolysis of the substrate.
For example, fumagillin, as well as its analogs TNP470 and
ovalicin, forms a covalent bond with the conserved His178 and
completely inhibits the enzyme by preventing substrate access
(Liu et al., 1998; Lowther et al., 1998). Both the MnII-form and
CoII-form selective inhibitors described here also occupy the
substrate-binding pocket, although only the MnII-form selec-
tive inhibitors actually ligate directly to the catalytic metal
ions. MnII-form selective inhibitors chelate with both metal
research papers
430 Xie et al.  Metalloform-selective inhibition of methionine aminopeptidase Acta Cryst. (2006). D62, 425–432
Table 2
Comparison of metal–ligand distances (Å) in the CoII and MnII forms of E. coli MetAP.
m1 site† m2 site†
PDB code‡ His171 Asp108 Glu235 Glu204 L1§ L2} Asp108 Glu235 Asp97 Asp97 L2} L3†† m1—m2 Inhibitor code‡‡
In the MnII form
1xnz 2.15 2.17 2.13 2.18 2.21 2.29 2.17 2.15 2.37 2.19 2.03 2.24 3.50 FCD (1)
2evm 2.23 2.24 2.15 2.18 2.24 2.32 2.13 2.15 2.34 2.13 2.10 2.17 3.54 FC2 (2)
2evc 2.22 2.22 2.16 2.16 2.22 2.28 2.16 2.19 2.40 2.11 2.10 2.20 3.53 FC3 (3)
2bb7 2.28 2.20 2.16 2.24 NA§§ 2.22 2.14 2.17 2.54 2.21 2.03 2.37 3.25 QMS
Mean 2.22 2.21 2.15 2.19 2.22 2.28 2.15 2.17 2.41 2.16 2.07 2.25 3.46
SD 0.05 0.03 0.01 0.03 0.02 0.04 0.02 0.02 0.09 0.05 0.04 0.09 0.14
In the CoII form
2evo 2.09 2.12 2.00 2.10 NA§§ 1.93 2.09 2.13 2.28 2.18 2.04 2.32 3.13 CT0 (4)
1yvm 2.09 2.05 2.07 2.19 NA§§ 1.93 1.93 2.17 2.45 2.10 2.07 2.17 3.13 TMG
3mat 2.15 1.92 2.17 2.46 2.48 2.07 2.06 2.19 2.62 2.07 1.87 2.35 3.33 AHH
1c21 2.11 2.01 2.00 2.09 3.23 2.03 2.08 2.21 2.33 2.20 2.24 2.23 3.31 MET
1c22 2.14 1.97 2.02 2.06 3.16 1.99 2.03 2.12 2.33 2.12 2.16 2.30 3.38 MF3
1c23 2.10 1.85 2.07 2.37 2.49 2.10 2.06 2.17 2.36 2.10 2.13 2.26 3.27 MPH
1c24 2.11 1.89 2.06 2.36 2.60 2.26 2.04 2.09 2.35 2.13 2.35 2.29 3.23 MPJ
1c27 2.13 1.85 2.07 2.28 2.60 2.16 2.00 2.19 2.34 2.25 2.31 2.43 3.23 NLP
Mean 2.12 1.96 2.06 2.24 2.76 2.06 2.04 2.16 2.38 2.14 2.15 2.29 3.25
SD 0.02 0.10 0.05 0.15 0.34 0.11 0.05 0.04 0.11 0.06 0.16 0.08 0.09
† m1 is either Mn1 or Co1 and m2 is either Mn2 or Co2. ‡ References for these structures: 2evm, 2evc and 2evo, this study; 1xnz, Ye et al. (2004); 2bb7, Huang et al. (2006); 1yvm,
Schiffmann et al. (2005); 3mat, Lowther, Orville et al. (1999); 1c21, 1c22, 1c23, 1c24 and 1c27, Lowther, Zhang et al. (1999). § Ligand L1 is usually an O atom of the bound
ligand. } Ligand L2 is usually an O atom bridging two metal ions either from the bound ligand or from a water molecule. †† Ligand L3 is either from a N atom of the bound inhibitor
or a conserved water molecule. ‡‡ Inhibitors: FCD, 5-(2-chlorophenyl)furan-2-carboxylic acid; QMS, N-(quinolin-8-yl)methanesulfonamide; TMG, thiabendazole; AHH, AHHpA-
Ala-Leu-Val-Phe-OMe; MET, methionine; MF3, trifluoromethionine; MPH, methionine phosphonic acid; MPJ, methionine phosphinic acid; NLP, norleucine phosphonic acid. §§ NA,
not available because no ligand is found at this position and Co1 is pentacoordinate.
ions at the dinuclear metal site, while the CoII-form selective
inhibitors recruit a third metal ion, forming a trimetallic
enzyme–metal–inhibitor complex. Thus, each of the two
classes, those that interact directly with the catalytic metals
and those that recruit a third metal to fill the substrate-binding
site, takes advantage of strong interactions with metal ions to
be able to block the active-site pocket. Although the potency
of each inhibitor can be understood in terms of the collected
hydrophobic and ligand–metal interactions seen in the crystal
structures, the important question that remains is why some
inhibitors are so selective for different metalloforms while
other ligands are not.
One way to view the interaction of the CoII form-selective
inhibitor (4) with the CoII form of MetAP, at least formally, is
that it is the 1:1 complex of (4) with CoII, preformed in solu-
tion, that binds to the enzyme through a combination of Lewis
acid–base coordination, hydrogen bonding and hydrophobic
interactions. Taking the formalized view that it is the metal
complex of (4) binding as a ‘hydrophobic Lewis acid’ to the
typical doubly metalated form of MetAP, rather than (4)
binding to a trimetalated form of MetAP (that probably does
not exist in solution), provides a simple explanation of the
selectivity of (4) for inhibition of CoII-MetAP over MnII-
MetAP. It is well documented that N,O-donor ligands such as
(4) coordinate much more strongly with softer CoII ions than
with relatively hard MnII ions. Thus, an important factor in the
CoII-MetAP selectivity of (4) compared with the MnII-MetAP
selectivity of inhibitors such as (1)–(3) is very likely to be the
much greater preference of CoII for soft versus hard (i.e. N
versus O) donor ligands (Hanzlik, 1976; Sigel & McCormick,
1970). We believe this explains why inhibitor (4) is so selective
for the CoII form of MetAP. It shows no significant activity
against the MnII form of MetAP and no crystals of its complex
with the MnII form could be obtained.
The binding of a third metal ion very close to the ‘classical’
MetAP dimetallic site has only recently been observed.
Douangamath et al. (2004) first reported a third CoII ion
bound to Staphylococcus aureus MetAP in the presence of
pyridine- or thiazole-containing methionine derivatives; in this
case His178 was the only point of direct interaction between
the third metal ion and an enzyme residue. More recently,
inhibitors such as thiabendazole (Schiffmann et al., 2005) and
quinolinyl sulfonamide (Huang et al., 2006) were found to bind
with a third CoII or MnII ion to E. coli MetAP by coordinating
to residue His79 instead of His178. This latter mode of binding
is exactly what we see in our CoII-form structure with (4). Both
His79 and His178 are conserved in all MetAPs; thus, this
recruitment of a third metal could conceivably also occur with
other MetAPs as well and could be a common mechanism of
inhibition for many N,N- or O,N-donor MetAP inhibitors that
have been discovered using an in vitro assay with a high
concentration of CoII ion.
The reason for the superb selectivity of ligands (1)–(3) for
MnII-MetAP versus other metalloforms is not entirely clear
but is probably also related largely to the hard/soft prefer-
ences of MnII for ligands. Thus, phenylfuran carboxylates such
as (1)–(3) containing only hard O-donor atoms should make
better ligands for MnII than for CoII. Comparing the relevant
metal–ligand distances has revealed some subtle potential
differences between the CoII and MnII forms. However, the
importance of these differences in determining the metallo-
form selectivity will certainly need further evaluation. Leaving
the phenylfuran carboxylate core intact, modification of other
substituents on the MnII-form selective inhibitors resulted in
parallel shifts in inhibitory potencies among the different
metalloforms (Huang et al., 2005), indicating that the inter-
action of the carboxylate group with the metals at the di-
nuclear site is a major determinant in the metalloform
selectivity. The specific distance between the two coordinating
carboxyl O atoms and their specific approach to the metal ions
may uniquely satisfy the requirement for coordinating with
the MnII ions and make compounds such as (1)–(3) very
selective for the MnII form of MetAP. MnII ions are suggested
to be the in vivo metal for human type II MetAP (Wang et al.,
2003) and could also be the in vivo metal for other MetAPs.
Although we do not fully understand the mechanisms
governing the metalation of apo-MetAP in cells, the MnII-
form selective inhibitors we have obtained from high-
throughput screening, along with other inhibitors with
different selectivity profiles, will be useful tools in defining
which metalloforms of MetAP are important under physio-
logical conditions in living cells.
In summary, structural analysis of the complexes of E. coli
MetAP with the MnII-form and CoII-form selective inhibitors
have provided insights into the structural basis of their
metalloform selectivity. The unexpected unique binding mode
of the CoII-form selective inhibitor (4) is consistent with its
high potency and selectivity profile. Its high selectivity towards
the CoII-form of the enzyme is explained, at least in part, by its
excellent capability of coordinating with soft CoII ions. The
superb selectivity of the MnII-form selective inhibitors (1)–(3)
is not entirely understood, but may be related to their unique
coordination with the MnII ions at the dinuclear site using the
carboxylate group.
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